Bio-Techne Q3 revenue falls 2% to $311.4 million; adjusted EPS $0.53 vs. $0.56
Bio-Techne reported third-quarter fiscal 2026 results for the quarter ended March 31, 2026, with net sales down 2% to $311.4 million. GAAP diluted EPS rose to $0.32 from $0.14, but adjusted diluted EPS fell to $0.53 from $0.56, and the company said demand from biotech customers has not yet broadly recovered. The company also declared a quarterly dividend of $0.08 per share.
Key points
- Net sales fell 2% to $311.4 million; organic revenue also fell 2%, with foreign exchange adding 2%.
- GAAP diluted EPS was $0.32 versus $0.14; GAAP operating income rose 95% to $75.5 million.
- Adjusted diluted EPS was $0.53 versus $0.56, and adjusted operating margin was 34.2% versus 34.9%.
- Dividend of $0.08 per share is payable May 29, 2026, to shareholders of record on May 18, 2026.
The filing
Written by AI (Anthropic Claude, claude-haiku-5-5) on Nov 8, 2026, 12:56 AM ET, from the text of the filing and its press-release exhibits only. Written later: this filing was briefed after the fact, when past filings were added to the site, so the brief may be read with hindsight; the filing itself is the record of what was known on May 06, 2026.
Briefs are written by AI from the filing text (each brief's own page names the model) and can contain mistakes — open the filing before acting on anything. Impact (1-5) and tone are the model's reading of the filing for shareholders, not a price forecast. Not investment advice.